According to DelveInsight’s analysis, the Pulmonary Arterial Hypertension market size was ~USD 8 billion in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025. The market is poised for continued expansion through the forecast period (2026–2036), supported by a robust drug pipeline, rising disease awareness, evolving treatment guidelines, and novel mechanism-of-action therapies entering the commercial landscape. The Pulmonary Arterial Hypertension market research underscores that the growing prevalence of PAH across geographies, combined with increasing investments in rare disease drug development, is reshaping the competitive and therapeutic landscape globally.
Explore DelveInsight’s comprehensive coverage of the Pulmonary Arterial Hypertension market to unlock actionable insights and strategic intelligence for Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension Therapies
The current and emerging treatment landscape for PAH features a range of approved and investigational therapies across multiple drug classes and delivery mechanisms:
- TYVASO / TYVASO DPI / TREPROST
- Macitentan and tadalafil (OPSYNVI / YUVANCI)
- Sotatercept (WINREVAIR)
- Treprostinil (YUTREPIA)
- Seralutinib (GB002)
- And Others.
These therapies represent a broad spectrum of mechanisms – from prostacyclin-pathway agents to novel activin signaling modulators – offering clinicians increasingly targeted options for individualized patient management. The expanding portfolio reflects the depth of innovation now characterizing this once-neglected rare disease space.
PAH Overview and Diagnosis
Pulmonary Arterial Hypertension, characterized by increased pulmonary vascular resistance and arterial pressure, affects an estimated 15–60 per million of the population and is more commonly diagnosed in women. PAH causes a range of nonspecific symptoms (including breathlessness, fatigue, chest pain, and weakness) and is associated with significant morbidity and mortality triggered by the debilitating progressive nature of the disease, which eventually leads to right heart failure and death. The effect of disease symptoms on the patient’s physical mobility and emotional state adversely affects health-related quality of life (HRQoL).
PAH is characterized by similar symptoms that appear during heart and lung conditions. Several techniques and blood tests – including chest X-rays, blood tests, cardiac catheterization, electrocardiograms, and echocardiograms – are used for diagnosing PAH. Early and accurate diagnosis remains one of the most critical challenges in managing PAH, as delayed identification significantly worsens patient prognosis and long-term outcomes. Improving diagnostic pathways is central to reducing the substantial burden PAH places on both patients and healthcare systems.
Pulmonary Arterial Hypertension Treatment Landscape
The four drug classes commonly used to treat PAH – PDE5 inhibitors, sGC stimulators, Endothelin Receptor Antagonists (ERAs), and prostacyclin analogs and agonists – target three major signaling pathways: prostacyclin, endothelin, and nitric oxide.
Macitentan is an endothelin receptor antagonist used to treat PAH, improving exercise capacity and reducing symptoms by lowering pulmonary vascular resistance. While the optimal initiation and adjustment of macitentan therapy remain unclear, it is considered a key option for managing PAH, especially for advanced cases. Prostacyclin medications are the oldest group used to treat PAH; these increase cAMP concentrations to produce pulmonary vasodilation.
Epoprostenol was the first drug introduced specifically for treating PAH and was approved by the US FDA in 1995. However, it was limited in its versatility by its restriction to IV use in the outpatient setting, requiring central venous access. There are several different prostacyclin derivatives with various modes of delivery that are improved; these include inhaled iloprost and treprostinil, SC or IV treprostinil, oral treprostinil diolamine, and an oral prostacyclin agonist selexipag. As the treatment paradigm shifts toward combination therapy and earlier initiation, the landscape is expected to grow more nuanced, with emerging agents targeting previously unexplored biological pathways further diversifying available options.
Pulmonary Arterial Hypertension Unmet Needs
The unmet needs of PAH outline the critical gaps between the current state of patient care, diagnosis, and the ideal and effective management of the disease. These gaps highlight the obstacles experienced by patients, clinicians, and researchers and identify potential solutions for future progress:
- Scarce epidemiology data limiting accurate disease burden assessment
- Lack of biomarker-based diagnosis tools for earlier, more precise detection
- Absence of curative targeted therapies capable of disease reversal
- Insufficient early diagnosis infrastructure and limited public awareness
- Need for a comprehensive, standardized treatment algorithm
- Gaps in long-term monitoring, patient support frameworks, and healthcare access equity
Addressing these unmet needs will be paramount to improving PAH outcomes and reducing the economic burden this disease places on patients, caregivers, and healthcare systems globally.
Pulmonary Arterial Hypertension Companies
A diverse range of pharmaceutical and biopharmaceutical companies are actively developing and commercializing therapies for PAH.
Key players include:
- United Therapeutics
- Mochida Pharmaceutical
- Johnson & Johnson
- Merck
- Gossamer Bio
- Pharmosa Biopharm / Liquidia
- Respira Therapeutics
- And others
These companies span large multinational pharmaceutical corporations and specialized rare disease innovators, each contributing to a competitive and rapidly evolving ecosystem. Strategic collaborations, licensing agreements, and pipeline acquisitions continue to accelerate the pace of drug development, particularly for next-generation inhaled and targeted biologic agents.
Pulmonary Arterial Hypertension Epidemiology
Key findings from PAH epidemiological analysis and forecast highlight the rising global disease burden and geographic distribution of cases:
- In 2025, the US accounted for the highest diagnosed prevalent cases of PAH with approximately 40,000 cases, which are expected to increase by 2036.
- Idiopathic/heritable PAH had the highest number of subtype-specific cases in the US in 2025 with nearly 19,000 cases, which is predicted to rise by 2036.
- In 2025, Germany reported the highest number of diagnosed prevalent cases of PAH among EU4 and the UK, with approximately 7,000 cases.
- In 2025, Japan reported nearly 19,000 diagnosed prevalent cases of PAH in females and nearly 5,000 cases in males, with numbers projected to rise by 2036.
These epidemiological findings underscore a growing patient population across major markets, reinforcing the urgency for more accessible diagnostics, expanded treatment access, and continued investment in PAH-specific drug development and patient registries.
Approved Therapies for Pulmonary Arterial Hypertension
- Inhaled treprostinil (YUTREPIA): Liquidia Technologies
Treprostinil (YUTREPIA), developed by Liquidia Technologies, is an inhaled dry powder formulation of treprostinil delivered through a convenient, palm-sized device designed using Liquidia’s PRINT technology to enhance deep-lung delivery to treat PAH.
In May 2025, FDA authorized YUTREPIA as a new therapeutic option for adults with PAH (WHO Group 1) and PH-ILD (WHO Group 3).
This approval marks a significant milestone in expanding the therapeutic toolkit available to PAH specialists, particularly for patients who require effective inhaled prostacyclin therapy with a more convenient delivery mechanism compared to existing options.
Pulmonary Arterial Hypertension Drug Updates
Recent developments reflect a dynamic and fast-moving landscape in PAH drug development:
- United Therapeutics intends to submit a New Drug Application (NDA) for ralinepag to the US Food and Drug Administration (FDA) by the second half of 2026.
- In February 2026, Gossamer Bio announced topline Phase III results for seralutinib, an investigational inhaled therapy for adults with PAH.
- In May 2025, the FDA officially approved Liquidia Corporation’s treprostinil inhalation powder (YUTREPIA) for the treatment of PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD) in adults.
These updates signal accelerating momentum in the PAH pipeline, with multiple late-stage candidates approaching regulatory milestones that could meaningfully shift the treatment standard of care within the coming forecast years.
Pulmonary Arterial Hypertension Market Outlook
Current therapies primarily work by dilating pulmonary blood vessels to reduce resistance and improve heart function, with treatment strategies guided by risk assessment based on clinical, functional, and hemodynamic parameters to achieve a low-risk status and improve outcomes such as survival, quality of life, and symptom control. The main drug classes used include PDE5 inhibitors, sGC stimulators, endothelin receptor antagonists, and prostacyclin analogs/agonists, which target the nitric oxide, endothelin, and prostacyclin pathways.
There are several Pulmonary Arterial Hypertension marketed drugs, each with distinct mechanisms. TYVASO/TYVASO DPI/TREPROSTINIL, ORENITRAM, and OPSYNVI/YUVANCI target prostacyclin pathways. Sotatercept (WINREVAIR) modulates signaling to improve vascular function.
The emerging therapies developed to treat PAH patients include late-stage and mid-stage candidates. As per DelveInsight’s estimates, the potential drugs that can mark a significant change in the forecast period include seralutinib (GB-002), treprostinil liposomal (L-606), Ralinepag, and others.
Pulmonary Arterial Hypertension market insight reveals the following regional breakdowns:
- The PAH market size of EU4 and the UK was estimated to be approximately USD 400 million in 2025.
- Among EU4 and the UK, Germany accounted for the highest PAH market share with approximately USD 100 million in 2025, followed by France and the UK with approximately USD 80 million each in 2025.
- In 2025, the PAH market size was approximately USD 300 million in Japan, which is anticipated to increase during the forecast period (2026–2036).
The Pulmonary Arterial Hypertension market trends indicate a clear shift toward combination therapies, earlier initiation strategies, and biologic agents targeting novel molecular pathways. As the pipeline matures and new approvals emerge, the global PAH market is expected to witness sustained double-digit growth over the coming decade, driven by both volume growth in diagnosed patient populations and the premium pricing of innovative agents entering the therapeutic landscape.
Access the latest Pulmonary Arterial Hypertension market research, epidemiology forecasts, and pipeline analysis to stay ahead in the evolving Pulmonary Arterial Hypertension treatment landscape.
Conclusion
The global PAH market is undergoing a pivotal transformation, shaped by scientific advancement, regulatory progress, and an expanding patient population. Despite meaningful therapeutic progress, significant unmet needs persist – from delayed diagnosis to the absence of curative treatments – making continued investment in research and innovation essential. With a robust pipeline, increasing regulatory approvals, and growing cross-border collaboration, the outlook for PAH patients and market stakeholders remains decisively optimistic through 2036 and beyond.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
